Classification of stimuli-responsive polymers as anticancer drug delivery systems. 2015

Bita Taghizadeh, and Shahrouz Taranejoo, and Seyed Ali Monemian, and Zoha Salehi Moghaddam, and Karim Daliri, and Hossein Derakhshankhah, and Zaynab Derakhshani
Institute of Biochemistry and Biophysics, University of Tehran , Tehran , Iran .

Although several anticancer drugs have been introduced as chemotherapeutic agents, the effective treatment of cancer remains a challenge. Major limitations in the application of anticancer drugs include their nonspecificity, wide biodistribution, short half-life, low concentration in tumor tissue and systemic toxicity. Drug delivery to the tumor site has become feasible in recent years, and recent advances in the development of new drug delivery systems for controlled drug release in tumor tissues with reduced side effects show great promise. In this field, the use of biodegradable polymers as drug carriers has attracted the most attention. However, drug release is still difficult to control even when a polymeric drug carrier is used. The design of pharmaceutical polymers that respond to external stimuli (known as stimuli-responsive polymers) such as temperature, pH, electric or magnetic field, enzymes, ultrasound waves, etc. appears to be a successful approach. In these systems, drug release is triggered by different stimuli. The purpose of this review is to summarize different types of polymeric drug carriers and stimuli, in addition to the combination use of stimuli in order to achieve a better controlled drug release, and it discusses their potential strengths and applications. A survey of the recent literature on various stimuli-responsive drug delivery systems is also provided and perspectives on possible future developments in controlled drug release at tumor site have been discussed.

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011108 Polymers Compounds formed by the joining of smaller, usually repeating, units linked by covalent bonds. These compounds often form large macromolecules (e.g., BIOPOLYMERS; PLASTICS). Polymer
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D006358 Hot Temperature Presence of warmth or heat or a temperature notably higher than an accustomed norm. Heat,Hot Temperatures,Temperature, Hot,Temperatures, Hot
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D006867 Hydrolases Any member of the class of enzymes that catalyze the cleavage of the substrate and the addition of water to the resulting molecules, e.g., ESTERASES, glycosidases (GLYCOSIDE HYDROLASES), lipases, NUCLEOTIDASES, peptidases (PEPTIDE HYDROLASES), and phosphatases (PHOSPHORIC MONOESTER HYDROLASES). EC 3. Hydrolase
D006868 Hydrolysis The process of cleaving a chemical compound by the addition of a molecule of water.

Related Publications

Bita Taghizadeh, and Shahrouz Taranejoo, and Seyed Ali Monemian, and Zoha Salehi Moghaddam, and Karim Daliri, and Hossein Derakhshankhah, and Zaynab Derakhshani
December 2014, Materials science & engineering. C, Materials for biological applications,
Bita Taghizadeh, and Shahrouz Taranejoo, and Seyed Ali Monemian, and Zoha Salehi Moghaddam, and Karim Daliri, and Hossein Derakhshankhah, and Zaynab Derakhshani
December 2020, Journal of controlled release : official journal of the Controlled Release Society,
Bita Taghizadeh, and Shahrouz Taranejoo, and Seyed Ali Monemian, and Zoha Salehi Moghaddam, and Karim Daliri, and Hossein Derakhshankhah, and Zaynab Derakhshani
January 2008, Journal of biomaterials science. Polymer edition,
Bita Taghizadeh, and Shahrouz Taranejoo, and Seyed Ali Monemian, and Zoha Salehi Moghaddam, and Karim Daliri, and Hossein Derakhshankhah, and Zaynab Derakhshani
April 2009, Biomedical materials (Bristol, England),
Bita Taghizadeh, and Shahrouz Taranejoo, and Seyed Ali Monemian, and Zoha Salehi Moghaddam, and Karim Daliri, and Hossein Derakhshankhah, and Zaynab Derakhshani
March 2015, Journal of nanoscience and nanotechnology,
Bita Taghizadeh, and Shahrouz Taranejoo, and Seyed Ali Monemian, and Zoha Salehi Moghaddam, and Karim Daliri, and Hossein Derakhshankhah, and Zaynab Derakhshani
July 2013, Mini reviews in medicinal chemistry,
Bita Taghizadeh, and Shahrouz Taranejoo, and Seyed Ali Monemian, and Zoha Salehi Moghaddam, and Karim Daliri, and Hossein Derakhshankhah, and Zaynab Derakhshani
December 2021, Pharmaceutics,
Bita Taghizadeh, and Shahrouz Taranejoo, and Seyed Ali Monemian, and Zoha Salehi Moghaddam, and Karim Daliri, and Hossein Derakhshankhah, and Zaynab Derakhshani
April 2008, Current drug delivery,
Bita Taghizadeh, and Shahrouz Taranejoo, and Seyed Ali Monemian, and Zoha Salehi Moghaddam, and Karim Daliri, and Hossein Derakhshankhah, and Zaynab Derakhshani
May 2020, Molecular pharmaceutics,
Bita Taghizadeh, and Shahrouz Taranejoo, and Seyed Ali Monemian, and Zoha Salehi Moghaddam, and Karim Daliri, and Hossein Derakhshankhah, and Zaynab Derakhshani
July 2005, Expert review of medical devices,
Copied contents to your clipboard!